NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $3.53 -0.36 (-9.25%) Closing price 04:00 PM EasternExtended Trading$3.54 +0.01 (+0.28%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$3.51▼$3.9050-Day Range$3.48▼$5.1752-Week Range$2.20▼$7.95Volume130,050 shsAverage Volume290,627 shsMarket Capitalization$217.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.20Consensus RatingHold Company Overview TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches. Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply. TriSalus offers interventional oncology devices, including the TriNav Infusion System, which is designed to support localized delivery of treatments while helping limit drug diversion away from the targeted tumor. TriSalus also develops investigational immunotherapy combinations intended to work with its delivery platform, including programs involving immune checkpoint inhibitors and other cancer treatments. The company’s clinical and commercial activities are primarily focused on oncology care in the United States, with an emphasis on hepatocellular carcinoma, intrahepatic cholangiocarcinoma and metastatic pancreatic cancer.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreTLSI MarketRank™: 2.03825063528 of 5 starsTriSalus Life Sciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 633rd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingTriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $10.20, representing about 189.8% upside from its current price of $3.52.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.53) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.68% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 20.11, which indicates bearish sentiment.Change versus previous monthShort interest in TriSalus Life Sciences has recently increased by 2.94%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentTriSalus Life Sciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for TriSalus Life Sciences this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,726.00 in company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesTriSalus Life Sciences (NASDAQ:TLSI) Stock Jumps 0.8% - Time to Buy?October 27, 2026 | americanbankingnews.comTriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference CallOctober 20, 2026 | businesswire.comThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.November 5 at 1:00 AM | Brownstone Research (Ad)H.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)October 3, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH), TriSalus Life Sciences (TLSI) and Immuneering (IMRX)September 24, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: TriSalus Life Sciences (TLSI) and Eli Lilly & Co (LLY)September 24, 2026 | theglobeandmail.comTriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav AdvanceSeptember 24, 2026 | marketscreener.comMUpdate: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav AdvanceSeptember 23, 2026 | finance.yahoo.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 at the beginning of the year. Since then, TLSI shares have decreased by 49.6% and is now trading at $3.52. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $11.41 million for the quarter, compared to analysts' expectations of $10.27 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? TriSalus Life Sciences' top institutional shareholders include CWA Asset Management Group LLC (0.12%) and Provenance Wealth Advisors LLC (0.04%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Mats Wahlstrom, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include Definium Therapeutics (DFTX), Palantir Technologies (PLTR), Solid Biosciences (SLDB), Amprius Technologies (AMPX), Cabaletta Bio (CABA), Merck & Co., Inc. (MRK) and ExxonMobil (XOM). Company Calendar Last Earnings8/06/2026Today11/05/2026Next Earnings (Estimated)11/10/2026Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, TLSI's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees102Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$10.20 High Price Target$12.00 Low Price Target$7.00 Potential Upside/Downside+189.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-62.59% Pretax Margin-62.56% Return on EquityN/A Return on Assets-64.47% Debt Debt-to-Equity Ratio5.05 Current Ratio5.35 Quick Ratio4.97 Sales & Book Value Annual Sales$45.15 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-5.19Miscellaneous Outstanding Shares61,580,000Free Float51,538,000Market Cap$217.38 million OptionableOptionable Beta0.50 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:TLSI) was last updated on 11/5/2026 by MarketBeat.com Staff. From Our PartnersGOP wipe out … but here’s WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensi...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | SponsoredThis NASDAQ company just signed a 50-year Army dealChina controls more than 90% of global rare earth processing. A new Pentagon restriction on certain Chinese-or...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSI Stock Alerts